The Melanoma Diagnostics Therapeutics Market is seeing steady development as healthcare providers focus on earlier melanoma detection and more targeted treatment options. According to WiseGuyReports, the market is expected to grow from USD 5.5 billion in 2025 to USD 10.2 billion by 2035 at a 6.4% CAGR.

Innovation is being driven by artificial intelligence, advanced imaging, molecular testing, and genomic technologies. Digital health and telemedicine are also supporting remote diagnostic evaluations and follow-up care, creating a more connected approach to melanoma management.

The market covers biopsy, imaging, blood tests, and genetic testing. Genetic testing was valued at USD 1.8 billion in 2024 and is projected to reach USD 2.7 billion by 2035, reflecting the growing role of genetic information in personalized treatment strategies.

Hospitals, diagnostic laboratories, research institutes, and specialized clinics are the main end users. North America currently holds the largest regional position, while Europe remains significant and Asia-Pacific offers additional opportunities through improving healthcare infrastructure and greater awareness.

The market has further potential through biomarker discovery, companion diagnostics, AI-assisted detection, and personalized immunotherapies. Continued R&D investment and expansion of screening programs could help broaden access to advanced melanoma diagnostics and treatments.